Purinergic signaling: a potential therapeutic target for ischemic stroke

Lu Wang,Ying-Jie Li,Xu Yang,Bo Yang,Xin Zhang,Jing Zhang,Qi Zhang,Xu-Dong Cheng,Jian-Hong Wang,Neng-Wei Yu
DOI: https://doi.org/10.1007/s11302-022-09905-y
2022-01-01
Purinergic Signalling
Abstract:Pathogenesis of ischemic stroke is mainly characterized by thrombosis and neuroinflammation. Purinergic signaling pathway constitutes adenosine triphosphate (ATP), adenosine diphosphate (ADP), adenosine monophosphate (AMP), and adenosine (ADO). ATP is hydrolyzed to ADP and then to AMP by extracellular nucleotidase CD39; AMP is subsequently converted to adenosine by CD73. All these nucleotides and nucleosides act on purinergic receptors protecting against thrombosis and inhibit inflammation. In addition, many physical methods have been found to play a neuroprotective role through purinergic signaling. This review mainly introduces the role and potential mechanism of purinergic signalings in the treatment of ischemic stroke, so as to provide reference for seeking new treatment methods for stroke.
What problem does this paper attempt to address?